UroGen Pharma Ltd. (URGN) P/E Ratio History
Historical price-to-earnings valuation from 2017 to 2017
Loading P/E history...
URGN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, UroGen Pharma Ltd. (URGN) trades at a price-to-earnings ratio of -8.3x, with a stock price of $26.59 and trailing twelve-month earnings per share of $-2.65.
The current P/E is 105% below its 5-year average of 177.9x. Over the past five years, URGN's P/E has ranged from a low of 177.9x to a high of 177.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, URGN trades at a 137% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, URGN trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our URGN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
URGN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 36.3 | 4.85Best | +1883%Best | |
| $7B | 15.5Lowest | - | +1747% | |
| $2B | 25.3 | - | +419% | |
| $536B | 38.4 | - | -58% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
URGN Historical P/E Data (2017–2017)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2017 Q3 | Sat Sep 30 2017 00:00:00 GM | $31.52 | $0.18 | 177.9x | +0% |
Average P/E for displayed period: 177.9x
See URGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs URGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare URGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonURGN — Frequently Asked Questions
Quick answers to the most common questions about buying URGN stock.
Is URGN stock overvalued or undervalued?
URGN trades at -8.3x P/E, below its 5-year average of 177.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does URGN's valuation compare to peers?
UroGen Pharma Ltd. P/E of -8.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is URGN's PEG ratio?
URGN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2017-2017.